Invivoscribe Marketing, Author at Invivoscribe

About Invivoscribe Marketing

This author has not yet filled in any details.
So far Invivoscribe Marketing has created 136 blog entries.

From prognostication to precision in acute myeloid leukemia

Invivoscribe Marketing2025-05-08T16:47:49-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3 ITD mutated AML

Invivoscribe Marketing2025-05-09T09:20:30-07:00May 8th, 2025|2025 Publications, Featured Publications, Publications|

Invivoscribe Announces Registration of the LeukoStrat^® CDx FLT3 Mutation Assay in the United Kingdom and Switzerland

Invivoscribe Marketing2025-03-28T10:05:45-07:00March 27th, 2025|2025 Press Releases, Press Releases|

Leveraging Highly Sensitive NGS FLT3-ITD and NPM1 MRD Assessments in AML

Invivoscribe Marketing2024-12-18T09:49:08-08:00December 7th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Leveraging Highly Sensitive NGS Assays for Clonality, SHM and MRD Assessments

Invivoscribe Marketing2024-10-01T16:51:20-07:00September 23rd, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Innovations in MRD Detection: Leveraging NGS to Gain Insights into Multiple Myeloma and B-ALL

Invivoscribe Marketing2024-09-25T09:19:32-07:00September 17th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 02

Invivoscribe Marketing2024-09-25T10:07:41-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments – Part 01

Invivoscribe Marketing2024-09-25T10:14:27-07:00June 25th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Clonality and Measurable Residual Disease (MRD) Testing on the Illumina NextSeq Sequencers

Invivoscribe Marketing2024-06-21T12:55:12-07:00June 21st, 2024|2024 Publications, Featured Publications, Publications|

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

Invivoscribe Marketing2024-05-07T17:44:56-07:00May 8th, 2024|2024 Press Releases, Press Releases|

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Invivoscribe Marketing2024-05-02T11:47:00-07:00May 2nd, 2024|2024 Publications, Featured Publications, Publications|

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

Invivoscribe Marketing2024-04-01T16:59:27-07:00March 20th, 2024|2024 Videos, Featured Videos, Videos|

Watch video

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Invivoscribe Marketing2024-03-26T13:55:01-07:00March 20th, 2024|2024 Publications, Featured Publications, Publications|

Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myeloma

Invivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|2024 Publications, Featured Publications, Publications|

Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell Neoplasms

Invivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|2024 Publications, Featured Publications, Publications|

The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

Invivoscribe Marketing2024-02-08T15:09:04-08:00November 16th, 2023|2023 Videos, Featured Videos, Videos|

Watch video

Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA

Invivoscribe Marketing2023-07-20T17:27:41-07:00July 21st, 2023|2023 Press Releases, Press Releases|

MRD Applications and Analysis

Invivoscribe Marketing2023-07-11T18:20:48-07:00June 20th, 2023|2023 Videos, Featured Videos, Videos|

Watch video

Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research

Invivoscribe Marketing2023-06-05T12:37:16-07:00June 2nd, 2023|2023 Press Releases, Press Releases|

NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers

Invivoscribe Marketing2023-06-06T16:30:52-07:00May 31st, 2023|2023 Videos, Featured Videos, Videos|

Watch video

Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

Invivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|2023 Press Releases, Press Releases|

Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay

Invivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|2023 Press Releases, Press Releases|

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant

Invivoscribe Marketing2024-08-02T14:22:45-07:00March 7th, 2023|2023 Publications, Featured Publications, Publications|

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

Invivoscribe Marketing2023-03-09T08:51:36-08:00February 28th, 2023|2023 Videos, Featured Videos, Videos|

Watch video

Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in China

Invivoscribe Marketing2023-02-23T06:28:40-08:00February 23rd, 2023|2023 Press Releases, Press Releases|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

About Invivoscribe Marketing

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.